TriangleFOR PATIENTS · SOURCE READING
Treatment of Primary CNS Lymphoma
Source: Primary CNS Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 25, 2023 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed primary central nervous system (CNS) lymphoma may include the following:
Source links and citations
Whole-brain radiation therapy.
Source links and citations
Chemotherapy with or without radiation therapy.
Source links and citations
Targeted therapy alone (rituximab, nivolumab, or ibrutinib).
Source links and citations
Targeted therapy (rituximab) and chemotherapy.
High-dose chemotherapy and stem cell transplant.
Source links and citations
A clinical trial of high-dose chemotherapy followed by whole-brain radiation therapy, stem cell transplant, and/or targeted therapy.
Source links and citations
A clinical trial of chemotherapy with or without stem cell transplant.
A clinical trial of targeted therapy (rituximab and ibrutinib) and chemotherapy.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice